Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
UCB Pharmaceuticals
Sort By
Newest First
Sign in
1 / 1
1 / 1
CDMO
UCB Announces FDA Approvals for BIMZELX for Psoriatic Arthritis, Axial Spondyloarthritis, and Ankylosing Spondylitis
UCB
PR-09-24-NI-13
Sep 23, 2024
Expansion
UCB to Build New Biotech Manufacturing Plant in Belgium
UCB
PR-M01-20-NI-004
Jan 02, 2020
FDA Approval
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
UCB
PR-M04-19-NI-013
Apr 04, 2019
FDA Approval
UCB Given FDA Okay for Anti-Arthritis Drug
Emilie Branch
Pharma's Almanac
PAO-M04-19-NI-008
Apr 02, 2019
Acquisition
UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off
UCB
PR-M04-18-NI-32
Apr 10, 2018
Innovation
CIMZIA® (certolizumab pegol) Label Change Marks Important Advance for European Women of Childbearing Age With Chronic Rheumatic Disease
UCB
PR-M01-18-NI-036
Jan 12, 2018
